Telefon ve e-posta Desteği
Sıkça Sorulan Sorular
Yazarlar İçin Teknik Bilgiler
İletişim Bilgileri
Ana Sayfaya Dönüş
 

Kongre Takvimi
Buradaki bilgiler JournalAgent™ online dergicilik sisteminden alınmaktadır.

The Anatolian Journal of Cardiology

[Anatol J Cardiol]
Anatol J Cardiol. 2006; 6(Suppl 2): 44-48

Treatment of atrial fibrillation in hypertrophic cardiomyopathy

Khashayar Hematpour1, Jonathan S. Steinberg1
Division of Cardiology, St. Luke's-Roosevelt Hospital Center, New York, NY, USA

Atrial fibrillation (AF) is present in 5 percent of hypertrophic cardiomyopathy (HCM) patients at the time of diagnosis. Ostial pulmonary vein (PV) diameter is increased in patients with AF as well as hypertensive patients. These findings support the theory that the cascade of events leading to diastolic dysfunction might predispose a person to AF by stretching the PVs. This mechanism is likely relevant to AF in HCM as well. The recognition that AF often times arises from the PVs has led to innovation of ablation techniques that target this zone to electrically isolate the PVs from the left atrium (LA). Anticoagulation is the cornerstone of AF treatment. Additional AF treatment in HCM patients de- pends on the initial decision regarding need for surgical intervention, whether or not AF is permanent, and the severity of symptoms in pati- ents with non-permanent AF. If surgery is planned, correction of the arrhythmia with MAZE procedure, which isolates the arrhythmogenic foci, at the time of myectomy is an option to consider. The goal in HCM patients with permanent AF is to control the heart rate whether by chronic medications or through ablate + pace procedure. Based on the severity of symptoms, HCM patients with non-permanent AF will be treated with either the rate control strategy (β-blockers/calcium channel blocker) or the rhythm control strategy (PV ablation, antiarrhyth- mic drugs, or radiofrequency ablation of the LA). This is because adverse effects of antiarrhythmics and complications after invasive proce- dures are justifiable only in HCM patients who experience severe symptoms.

Keywords: Cardiomyopathy, hypertrophy, atrial fibrillation, pulmonary vein, ablation


Khashayar Hematpour, Jonathan S. Steinberg. Treatment of atrial fibrillation in hypertrophic cardiomyopathy. Anatol J Cardiol. 2006; 6(Suppl 2): 44-48


ARAÇLAR
Tam Metin PDF
Yazdır
Alıntıyı İndir
RIS
EndNote
BibTex
Medlars
Procite
Reference Manager
E-Postala
Paylaş


Benzer makaleler
PubMed
Google Scholar




 

 
 

Online Kongre Hizmetleri
Kongre Web Sitesi
Bildiri Özeti Toplama ve Değerlendirme
Online Kayıt ve Konaklama
Elektronik Poster (e-poster)
Video Podcast, WebCast
Bilimsel Program Düzenleyici
Bildiri Özeti ve Tam Metin CD'leri
 

Online Kurumsal Hizmetler
Dernekler İçin Web Siteleri
Hakemli Dergiler İçin Online Makale Toplama
   ve Değerlendirme

Uluslararası Dizin Danışmanlığı
PubMed®, LinkOut® Hizmetleri
Online Çalışma Grupları
 

Referans
Çalıştığımız Online Hakemli Dergiler
Destek Verdiğimiz Kongreler
Yazarlar İçin Teknik Bilgiler

İletişim
Bize Ulaşın
LookUs

 
 
1999 - 2019 © LookUs Scientific

Bu sitede sözü edilen uygulamalara ait teknoloji, uygulama metodu, ekran görünüşleri; ticari marka, ticari görünüm, kanun dışı rekabet ve başka kanunlarca; yerel ve uluslararası copyright düzenlemeleri ile korunmuştur. Site üzerindeki herhangi bir metin ve imaj LookUs Bilişim Hizmetleri Ltd.'nin açık ve net izni olmadan kopyalanamaz veya dağıtılamaz.
Metinler ve şekiller içinde geçen gerçek şirket ve ürün adları, ilgili firmaların ticari markaları olabilir.